Spero Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Spero Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Buyback Yield
| Total Shareholder Yield | n/a |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
Spero Therapeutics: Tebipenem's FDA Path Supports A Speculative Buy
Summary Spero Therapeutics' lead asset is an oral carbapenem tebipenem for cUTI. This asset achieved Phase 3 noninferiority. In fact, this data supports GSK’s NDA resubmission strategy. The prior FDA setback from ADAPT-PO was addressed through PIVOT-PO. The new PIVOT-PO trial was actually stopped early after strong interim efficacy results. So, I believe their data is quite favorable this time. Also, SPRO’s partnership economics are meaningful. They can soon receive sizable resubmission milestone payments and royalties tied to commercialization. In my view, SPRO’s current valuation seems too low relative to the TAM they can unlock with tebipenem. So, I rate them a speculative 'Buy' at these levels. Read the full article on Seeking AlphaSpero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 26%
Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shareholders would be excited to see that the share price has had a great...
Positive Phase III Efficacy Will Unlock Expanded Antibiotic Markets
The downward revision in Spero Therapeutics’ consensus price target largely reflects declines in its future P/E multiple and net profit margin, resulting in a lower fair value estimate of $4.00. What's in the News The phase III PIVOT-PO trial of tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), was stopped early due to efficacy, following an Independent Data Monitoring Committee recommendation.Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans?
NasdaqGS:SPRO 1 Year Share Price vs Fair Value Explore Spero Therapeutics's Fair Values from the Community and select...Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price
With a price-to-sales (or "P/S") ratio of 3.1x Spero Therapeutics, Inc. ( NASDAQ:SPRO ) may be sending very bullish...
Successful Phase III Trial Will Redefine Treatment For Complicated UTIs
Successful PIVOT-PO trial and regulatory approval could propel revenue growth, leveraging a strategic partnership with GSK for commercialization.Spero Therapeutics, Inc. (NASDAQ:SPRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
To the annoyance of some shareholders, Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shares are down a considerable 27% in...Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal
Summary Spero Therapeutics' tebipenem, an oral carbapenem for cUTIs, has high approval potential, supported by a successful phase 3 trial and a GSK licensing deal. The need for oral carbapenems is critical due to rising resistance to current oral treatments for complicated urinary tract infections. Tebipenem's success in the confirmatory phase 3 trial is highly probable, given its prior phase 3 success and publication in NEJM. Despite risks, SPRO's valuation is attractive, with significant upside potential from tebipenem milestones and possible pipeline progress. Read the full article on Seeking AlphaThere Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding
Spero Therapeutics, Inc.'s ( NASDAQ:SPRO ) price-to-sales (or "P/S") ratio of 0.5x might make it look like a strong buy...Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price
Spero Therapeutics, Inc.'s ( NASDAQ:SPRO ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong buy...Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Summary Spero Therapeutics, Inc. has continued to build and advance its pipeline over the past several months and is now on the verge of generating landmark data with multi-bagger potential. Spero has excellent downside protection and additional upside from the payments from the Tebipenem HBr deal with GSK. Spero's significant undervaluation and potential path forward are highlighted in the peer comparison. Read the full article on Seeking AlphaSpero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%
Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shares have continued their recent momentum with a 27% gain in the last month...Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
The Spero Therapeutics, Inc. ( NASDAQ:SPRO ) share price has done very well over the last month, posting an excellent...Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates
Today is shaping up negative for Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shareholders, with the analysts delivering a...Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth
Those holding Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shares would be relieved that the share price has rebounded 26...Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%
Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shareholders will have a reason to smile today, with the analysts making...We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if SPRO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SPRO's dividend payments have been increasing.
Dividend Yield vs Market
| Spero Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (SPRO) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.3% |
| Industry Average (Biotechs) | 2.5% |
| Analyst forecast (SPRO) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate SPRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SPRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate SPRO's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SPRO has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/20 02:07 |
| End of Day Share Price | 2026/05/20 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Spero Therapeutics, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Esther Lannie Hong | Berenberg |
| Jason Matthew Gerberry | BofA Global Research |
| Esther Lannie Hong | Brean Capital Historical (Janney Montgomery) |